Corrigendum to: "Analysis of T1c Prostate Cancers Treated at Very Low Prostate-Specific Antigen Levels" [Eur Urol 2009;55:610-6] (DOI:10.1016/j.eururo.2008.07.005);Analysis of T1c Prostate Cancers Treated at Very Low Prostate-Specific Antigen Levels

European Urology

Volumn 55, Issue 3, 2009, Pages 610-616

  Stephenson, Andrew J ^a   Jones, J Stephen ^a   Hernandez, Adrian V ^a   Ciezki, Jay P ^a   Gong, Michael C ^a   Klein, Eric A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Biopsy; Mass screening; Prostate specific antigen; Prostatectomy; Prostatic neoplasms; Radiation therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CLINICAL ASSESSMENT; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME;

EID: 58949092569     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.02.008     Document Type: Erratum

References (31)

1. American Urological Association (AUA). Prostate-specific antigen (PSA) best practice policy. Oncology, 2000;14:267-86.
2. Ohori M., Wheeler T.M., Dunn J.K., Stamey T.A., and Scardino P.T. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 152 (1994) 1714-1720
3. Epstein J.I., Chan D.W., Sokoll L.J., et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160 (1998) 2407-2411
4. Hugosson J., Aus G., Lilja H., Lodding P., and Pihl C.G. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 100 (2004) 1397-1405
5. Loeb S., Gonzalez C.M., Roehl K.A., et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol 175 (2006) 902-906
6. Graif T., Loeb S., Roehl K.A., et al. Under diagnosis and over diagnosis of prostate cancer. J Urol 178 (2007) 88-92
7. Jang T.L., Han M., Roehl K.A., Hawkins S.A., and Catalona W.J. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects. Urology 67 (2006) 343-348
8. Pelzer A.E., Bektic J., Akkad T., et al. Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml. J Urol 178 (2007) 93-97
9. Schröder F., van der Cruijsen-Koeter I., de Koning H., Vis A., Hoedemaeker R., and Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 163 (2000) 806-812
10. Aleman M., Karakiewicz P.I., Kupelian P., et al. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/ml: implications for screening. Urology 62 (2003) 70-74
11. Catalona W.J., Smith D.S., and Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277 (1997) 1452-1455
12. Smith R.A., Cokkinides V., and Eyre H.J. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin 56 (2006) 11-50
13. Thompson I.M., Ankerst D.P., Chi C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005) 66-70
14. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 g per milliliter. N Engl J Med 350 (2004) 2239-2246
15. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
16. Cagiannos I., Karakiewicz P., Graefen M., et al. Is year of radical prostatectomy a predictor of outcome in prostate cancer?. J Urol 171 (2004) 692-696
17. Dong F., Reuther A.M., Magi-Galluzzi C., Zhou M., Kupelian P.A., and Klein E.A. Pathologic stage migration has slowed in the late PSA era. Urology 70 (2007) 839-842
18. Renshaw A.A., Chang H., and D'Amico A.V. Estimation of tumor volume in radical prostatectomy specimens in routine clinical practice. Am J Clin Pathol 107 (1997) 704-708
19. Hernandez D.J., Nielsen M.E., Han M., et al. Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology 72 (2008) 172-177
20. Stephenson A.J., Kattan M.W., Eastham J.A., et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24 (2006) 3973-3978
21. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
22. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868-878
23. Postma R., Schröder F.H., van Leenders G.J.L.H., et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) - Section Rotterdam: a comparison of two rounds of screening. Eur Urol 52 (2007) 89-97
24. Sakr W.A., Grignon D.J., Crissman J.D., et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 8 (1994) 439-443
25. Harlan S.R., Cooperberg M.R., Elkin E.P., et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol 170 (2003) 1804-1807
26. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358 (2008) 1250-1261
27. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
28. Thompson I.M., Chi C., Ankerst D.P., et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98 (2006) 1128-1133
29. Eastham J.A., Riedel E., Scardino P.T., et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 289 (2003) 2695-2700
30. Lucia M.S., Epstein J.I., Goodman P.J., et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99 (2007) 1375-1383
31. Albertsen P.C., Hanley J.A., Barrows G.H., et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97 (2005) 1248-1253